Oppenheimer lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $350 from $375 and keeps an Outperform rating on the ...

Patients with well-compensated NASH cirrhosis and three metabolic risk factors were selected for inclusion in the study.

Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $203.59.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced that it will release its third-quarter 2024 ...

The Janus Henderson Biotech Innovation Fund continues to lead all biopharma and life sciences hedge funds after mixed results for the general strategy in September. Several funds lost money last month ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...

VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.

One much-anticipated drug that hit the mark in NASH, though, was Madrigal Pharma’s resmetirom, which was able to reduce fibrosis and reduced NAFLD activity scores in the phase 3 MAESTRO-NASH ...

As of October 18, 2024, Madrigal Pharmaceuticals Inc had a $4.7 billion market capitalization, putting it in the 70th percentile of companies in the Biotechnology industry. Madrigal Pharmaceuticals ...